CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:15 AM

CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of 5.56 Closing the day 10:45 at 5.76 -0.19 -3.19% With a day low of 5.56 and a total volume of 41,986.

CGIX Recent Posts: http://investorshangout.com/Cancer-Genetics-Inc-CGIX-88009/

CGIX Cancer Genetics Inc Recent Headline News

Cancer Genetics, Inc. to Present at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Mon Nov 17, 6:50AM CST
-- Cancer Genetics will present two posters on diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancers.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. Recognized in Deloitte's 2014 Technology Fast 500(TM) Awards
GlobeNewswire - Fri Nov 14, 7:06AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company"

, an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc to Present at Canaccord Genuity Medical Technology & Diagnostics Conference
GlobeNewswire - Thu Nov 13, 6:55AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company's CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, November 20, will profile over 80 public and private med-tech and diagnostic companies.
CGIX: 5.73 (-0.22)

Cancer Genetics wins second patent for FHACT test to improve cervical cancer detection for up to 2m women in the US each year
M2 - Wed Nov 12, 7:02AM CST
Cancer diagnostics company Cancer Genetics (NasdaqCM:CGIX) disclosed on Tuesday the receipt of the second US patent (US Patent No. 8,883,414) for its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients.
CGIX: 5.73 (-0.22)

RedChip Issues Research Note on Cancer Genetics
GlobeNewswire - Wed Nov 12, 7:00AM CST
RedChip Companies, Inc., today announced it has issued a research note on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc to Present on Company's Targeted Next-Generation Sequencing Panels at AMP
GlobeNewswire - Wed Nov 12, 6:55AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology's (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist Charles Ma, Ph.D., will present "Developing NGS-based Clinical Assays for Hematological Neoplasms at CGI" on Wednesday, November 12 at 3 p.m. EST. The talk, which is sponsored by Illumina, will cover the development and clinical utility of the company'sNGS panels for hematologic malignancies, specifically for CLL (chronic lymphocytic leukemia) and Myeloid disorders.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT(R)
GlobeNewswire - Tue Nov 11, 6:55AM CST
-- Company receives second patent (US Patent No. 8,883,414) for FHACT(R)
CGIX: 5.73 (-0.22)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.32 (-0.01), JRJC: 6.87 (+0.13), NAVB: 1.21 (-0.01), SANW: 3.68 (+0.16), PLPM: 1.60 (+0.02), RYN: 26.89 (+0.48), INFU: 2.87 (+0.02), LIOX: 5.08 (+0.12), DY: 25.97 (+0.30), MTZ: 24.55 (+0.45), CGIX: 5.73 (-0.22), MUX: 1.51 (+0.05), OREX: 5.67 (-0.01), URRE: 2.14 (unch), ACHN: 13.12 (+0.21), REN: 2.62 (+0.13), MPO: 2.82 (+0.17), AKBA: 14.50 (-0.74), TRX: 1.15 (+0.08), PLNR: 7.27 (+0.04)

Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:28AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:03AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 5.73 (-0.22)

Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 5.73 (-0.22)

Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 5.73 (-0.22)

Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 5.73 (-0.22)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CAE Boosts Fiscal 2027 Outlook; Transformation On Track

Revenue's down by a hair, but it's not as bleak as it seems. CAE Inc. (NASDAQ:CAE) just put its cards on the table for Q2 of fiscal 2027, and there's a mixed bag for us investors to chew over. Revenue dipped 2.6% year-over-year to $1,204.7 million. But hey, their adjusted EPS has climbed up to $0.33, a step up from $0.28 last year, which is a good sign of something right...

Ingram Micro Joins S&P SmallCap 600 Amid M&A Moves

Market Shufflin’ as Ingram Micro Steps In The constant ebb and flow of the stock market got right interesting with Ingram Micro Holding Corp. (NYSE: INGM) slated to crawl into the S&P SmallCap 600. This dance change-up is all thanks to Viatris Inc. (NASD: VTRS) looking to wrap up its acquisition of Pacira BioSciences (NASD: PCRX). With this deal sealing the fate of...

'Luz de las Naciones' Event: A Cultural Milestone

A Vibrant Showcase of Culture and Faith Grab your seatbelt, because when you hear about a cultural event lighting up the scene, especially one backed by The Church of Jesus Christ of Latter-day Saints, it means something's brewing. We're diving headfirst into 'Luz de las Naciones,' a celebration that's keeping its promise to highlight Latin America's zest and vibrant...

Elron Ventures Advances Dual-Use Tech Investment Plans

A Strategic Dance through Conferences Elron Ventures is gearing up for an action-packed November slate, aiming to flaunt its prowess in investment across burgeoning tech fields like Defense Tech, Deep Tech, Cybersecurity, and AI. Now, any seasoned investor knows these are the buzzy sectors that could just be the workhorses pulling the future market cart. But what makes...

GFL's Big Share Conversion: Impact and Implications

Unpacking GFL Environmental's Share Conversion Here's a doozy straight from the gritty world of finance: GFL Environmental Inc. (NYSE: GFL) has announced a hefty conversion of Series A Preferred Shares into a whopping 6,219,896 subordinate voting shares. That's right, those Series A Preferred Shares, helmed by HPS Investment Partners, LLC, are now converted and sold in a...

China's Double 11 Fest Rings in $264B in 2026

Shifting Gears at the 2026 Double 11 Festival You blinked, and another record was shattered. China's "Double 11" Shopping Festival, with its rhythmic frenzy and relentless countdowns, clocked a staggering RMB 1,776.4 billion this year—roughly US$264.4 billion. This ain't no ordinary sale, it's a financial juggernaut, folks. As these platforms duke it out for every yuan,...

DarioHealth Eyes Growth with Rising Revenue and Reduced Costs

Quarterly Earnings Reflect Strategic Forward Movement This quarter, DarioHealth (NASDAQ: DRIO) decided to crank up the volume on its long-haul strategy. They've managed a respectable 6% revenue increase over last year, clocking in at $5.3 million for the third quarter of 2026. It's a slight nudge up from the previous quarter too, where they sat at $5.2 million. Not...

Can BWIN, CCC, PCRX Deals Really Serve Shareholders?

Shareholder Stakes: Caught in Controversy Well, here we go again. These days, it seems like shareholder lawsuits are cropping up as regularly as sunrise. We've got Halper Sadeh LLC on a warpath, targeting potential legal missteps in the megadeals involving Baldwin Group (NASDAQ:BWIN), CCC Intelligent Solutions Holdings (NASDAQ:CCC), and Pacira BioSciences (NASDAQ:PCRX)....

Eli Radiopharma Clinches Big Series A, Eyes Milestones

Making Waves in Radiopharmaceuticals Some days, it's not just about the numbers—it’s about the shift in an entire field. Eli Radiopharma just closed a grand RMB 400 million Series A financing, paving a path that could redefine radiopharmaceuticals. Kinfolk over at Huagai Capital led the charge, teaming up with Bayland Capital and a throng of other backers. They’re...

BSR REIT's Q3 2026 Financials: Strategic Progress Made

BSR REIT Hits Strategic Milestones in Q3 Here's a bit of exciting news hitting us from BSR Real Estate Investment Trust. They've dropped their financial results for the third quarter of 2026. Packed with some solid gains, this quarter wasn't just about the numbers—it was about the moves they've been making underneath it all. So, let's break down what they're up to, and...